Company
Inmune Bio, Inc. (INMB)
Standardized SEC financial data for Inmune Bio, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001711754 · NASDAQ · Biological Products, (No Diagnostic Substances).
Revenue growth (YoY)
257.1%
Return on equity
-195.3%
ROIC
-344.0%
Free cash flow
-$23.6M
Debt / equity
0.64×
Current ratio
3.55×
EPS (diluted)
$-1.86
Ratios for fiscal year 2025, standardized from SEC filings.
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $11K | $181K | $374K | $155K | $14K | $50K |
| R&D expense |
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $22.0M | $74.8M | $52.2M | $35.8M | $20.9M | $24.8M |
| Total current assets |
Cash flow
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$8.9M | -$28.5M | -$22.7M | -$12.0M | -$33.4M | -$22.6M |
| Capital expenditures |
Get INMB data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/INMB/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/INMB/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"